samedan logo

 
 
spacer
home > ebr > winter 2003 > clinical applications of small molecule p38 map kinase inhibitors
PUBLICATIONS
European Biopharmaceutical Review

Clinical Applications of Small Molecule p38 MAP Kinase Inhibitors

Tumour necrosis factor alpha (TNF-a) and interleukin-1 beta (IL-1b) are pro-inflammatory cytokines that play a key role in the communication between cellular components (leukocytes, macrophages, endothelial cells and so on) that drive inflammatory processes underlying a broad range of diseases. Injectable biological therapies specifically targeting the inhibition of TNF-a (infliximab and etanercept) or IL-1 (anakinra) are clinically validated in the treatment of rheumatoid arthritis (RA), psoriatic arthritis, psoriasis and Crohn's disease (CD). TNF inhibitors in particular have become a gold standard of disease-modifying treatment in patients with severe RA.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Leslie Williams, Program Executive for Vertex's p38 MAP Kinase Development Team

Dr Leslie Williams is Program Executive for Vertex's p38 MAP kinase development team and is also Head of Drug Safety and Medical Writing at Vertex. Leslie joined Vertex in 2000 after seven years of clinical experience in medical information and Phase III and IV post-marketing safety surveillance at two major pharmaceutical companies. Leslie holds a Doctorate of Veterinary Medicine and is a Diplomat of the American College of Veterinary Anesthesiology. Prior to joining the pharmaceutical industry, Leslie served as a Faculty Member and Section Head of Anesthesia at Tufts University School of Veterinary Medicine.

spacer
Dr Leslie Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius Stedim Biotech Launches New Services for Mammalian Cell Bank Manufacturing

GOETTINGEN, Germany and GLASGOW, UK, August 08, 2019 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharmaceutical industry, today announced the launch of new services for mammalian cell bank manufacture under GMP conditions. These services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced contract testing organization (CTO) based in Glasgow, UK, and in Cambridge, Massachusetts, USA.
More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UKs Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement